Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferon-alpha: a clinical update.

P T Rieger1

  • 1The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

Cancer Practice
|November 1, 1995
PubMed
Summary
This summary is machine-generated.

Interferon-alpha (IFN-alpha) is an expanding cancer treatment. Comprehensive patient support and side effect management are crucial for successful IFN-alpha therapy and achieving therapeutic responses.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Breaking the silence.

ONS news·2002
Same author

The role of oncology nurses in gene therapy.

The Lancet. Oncology·2002
Same author

Planning for the future--the integration of genetics into cancer care.

Nursing outlook·2002
Same author

Pain management and oncology nursing practice.

Pain management nursing : official journal of the American Society of Pain Management Nurses·2001
Same author

Assessment and epidemiologic issues related to fatigue.

Cancer·2001
Same author

Oncology nurses' knowledge, practice, and educational needs regarding cancer genetics.

American journal of medical genetics·2001
Same journal

Darbepoetin alfa: a review of its use in patients with cancer.

Cancer practice·2002
Same journal

Cancer genetics: information sources for patients and families.

Cancer practice·2002
Same journal

Bladder cancer: epidemiology, diagnosis, and management.

Cancer practice·2002
Same journal

Patient and caregiver interest in internet-based cancer services.

Cancer practice·2002
Same journal

Tapestry: a retreat program of support for persons living with cancer.

Cancer practice·2002
Same journal

Viatical settlements: effects on terminally ill patients.

Cancer practice·2002
See all related articles

Area of Science:

  • Oncology
  • Immunotherapy

Background:

  • Interferon-alpha (IFN-alpha) has been utilized in cancer treatment since the 1980s.
  • Regulatory approval was granted in 1986, with ongoing investigational trials and anticipated expanded approvals.
  • The clinical benefits of IFN-alpha continue to be elucidated.

Purpose of the Study:

  • To highlight the challenges in managing patients undergoing IFN-alpha therapy.
  • To emphasize the importance of comprehensive patient care, including side effect management and support.
  • To underscore the role of patient education and healthcare team interventions in treatment adherence.

Main Methods:

  • Review of clinical trials and regulatory approvals of IFN-alpha.
  • Discussion of patient management strategies in oncology.

Related Experiment Videos

  • Analysis of patient support, side effect management, and education.

    • Main Results:

    • IFN-alpha therapy requires careful management of side effects.
    • Patient education and reassurance are key to improving adherence.
    • Healthcare team interventions significantly impact patient outcomes.

    Conclusions:

    • Effective management of side effects and robust patient support are essential for successful IFN-alpha cancer therapy.
    • Patient education and motivation empower individuals to continue treatment.
    • Proactive healthcare interventions enable patients to achieve therapeutic responses with IFN-alpha.